Unstable Angina Therapeutics Clinical Trials Market Review Report Available at MarketOptimizer.org
Dallas, TX (PRWEB) October 13, 2014 -- Unstable angina is angina pectoris caused by disruption of an atherosclerotic plaque with partial thrombosis and possibly embolization or vasospasm. It is characterized by at least one of the following:
- Occurs at rest or minimal exertion and usually lasts less than 20 minutes (if nitroglycerin is not administered)
- Being severe and described as flank pain, and of new onset (i.e., within 1 month)
- Occurs with a crescendo pattern (more severe, prolonged, or increased frequency than previously).
Fifty percent of people with unstable angina will have evidence of myocardial necrosis based on elevated cardiac serum markers such as creatine kinase isoenzyme (CK)-MB and troponin T or I, and thus have a diagnosis of non-ST elevation myocardial infarction.
Clinical trial report, “Unstable Angina Global Clinical Trials Review, H2, 2014″ provides data on the Unstable Angina clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Unstable Angina. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Unstable Angina.
Complete report available @ http://www.marketoptimizer.org/unstable-angina-global-clinical-trials-review-h2-2014.html .
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons To Buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=11399 .
Clinical Trial Overview of Top Companies:
- Sanofi
- Takeda Pharmaceutical Company Limited
- AstraZeneca PLC
- Pfizer Inc
- GlaxoSmithKline plc
- Biopure Corporation (Inactive)
- AtheroGenics, Inc. (Inactive)
- Alere Inc.
- Ablynx NV
Clinical Trial Overview of Top Institutes / Government:
- National Heart, Lung, and Blood Institute
- China Academy of Chinese Medical Sciences
- Massachusetts General Hospital
- Karolinska Institute
- Nanjing Medical University
- Deutsches Herzzentrum Munchen
- Semnan University of Medical Sciences
- Kanagawa PTCA Conference
- Population Health Research Institute
- University of Oslo
List of Tables
Unstable Angina Therapeutics, Global, Clinical Trials by Region, 2014* 7
Unstable Angina Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Unstable Angina Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Unstable Angina Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Unstable Angina Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Unstable Angina Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Unstable Angina Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Unstable Angina Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Unstable Angina to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Unstable Angina Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Unstable Angina Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Unstable Angina to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Unstable Angina Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Unstable Angina Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Unstable Angina Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Unstable Angina Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Unstable Angina Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Unstable Angina Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Unstable Angina Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Unstable Angina Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Unstable Angina Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Unstable Angina Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Unstable Angina Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Unstable Angina Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Unstable Angina Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Browse more reports on Pharmaceuticals Market @ http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .
About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, Market Optimizer, http://www.marketoptimizer.org/, +1 (888) 391-5441, [email protected]
Share this article